RNS Number : 2208W
Shield Therapeutics PLC
22 April 2021
Shield Therapeutics plc
("Shield" or the "Group")
Notice of Results
London, UK, 22 April 2021: Shield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru®/Accrufer® (ferric maltol), will announce its preliminary results for the year ended 31 December 2020 on Thursday 29 April 2021.
Analyst briefing
A briefing open to analysts will take place remotely via video conference call on Thursday 29 April 2021 at 09.30am. If you would like the details of this zoom meeting please contact Walbrook PR on [email protected]
For further information, please contact:
|
Shield Therapeutics plc
|
+44 (0) 191 511 8500
|
|
Tim Watts (CEO)
Hans-Peter Rudolf (CFO)
|
|
|
|
|
|
Peel Hunt
LLP - Nominated Adviser & Joint Broker
|
+44 (0) 20 7148 8900
|
|
James Steel / Christopher Golden
|
|
|
|
|
|
finnCap Ltd - Joint Broker
|
+44 (0) 20 7220 0500
|
|
Geoff Nash /
Alice Lane /
Matthew Radley
|
|
|
|
|
|
Walbrook PR - Financial PR & IR Adviser
|
+44 (0) 20 7933 8780
|
|
Paul McManus / Lianne Cawthorne
|
or [email protected]
|
|
|
|
|
About Shield
Shield is a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru ® /Accrufer ® (ferric maltol), a novel, stable, non-salt based oral therapy for adults with iron deficiency with or without anaemia.
Shield's lead product, Feraccru®/Accrufer®, has been approved for use in the United States, European Union, UK and Switzerland and has exclusive IP rights until the mid-2030s. The Group plans to launch Accrufer® in the US during 2021 through a highly experienced sales and marketing team. Feraccru® is already being commercialised in the UK and European Union by Norgine B.V., who also have the marketing rights in Australia and New Zealand. Shield also has an exclusive licence agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of Feraccru®/Accrufer® in China, Hong Kong, Macau and Taiwan.
For more information, please visit
www.shieldtherapeutics.com
. Follow Shield on Twitter @ShieldTx
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
[email protected] or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy.
END
NORBLGDSGBDDGBB